Continue to learn
Our recombinant protein platform uses genetic engineering technology to quickly identify potential antigens and modify their genes to improve their immunogenicity and integrate them into appropriate expression systems
With nearly 20 kinds of adjuvant raw materials, we are able to achieve independent design and production, controlled cost and quality, and got rid of dependence on raw materials import.
Our mRNA technology can realize the integration of nucleic acid+delivery, and the mRNA platform established by Makikon Biology has non-replication mRNA technology